No Products in the Cart

While the G8 is approximately 50% smaller than the current Dexcom G7 and features an extended 15-day wear time, the most significant innovation may be happening behind the scenes. The new sensor introduces adaptive accuracy technology, designed to continuously adjust to each user's physiology throughout the wear period to deliver more consistent and reliable glucose readings.
Dexcom also revealed plans for future multi-analyte monitoring capabilities that could allow users to track biomarkers beyond glucose, including ketones and potassium.
Although the G8 is still awaiting regulatory submission and is not expected to reach the market for several years, the announcement provides one of the clearest views of where diabetes technology may be heading.
One of the first things people will notice about the Dexcom G8 is its size.
According to Dexcom, the G8 is approximately half the size of the current G7 sensor and features a more compact square-shaped design with rounded corners. The adhesive patch has also been reduced, meaning less skin coverage and a more discreet appearance.
For people managing diabetes, a smaller CGM may offer several practical benefits:
While sensor size may seem like a small change, it reflects a growing industry trend toward making diabetes devices less intrusive and easier to live with.
The most significant innovation announced for the G8 is what Dexcom calls adaptive accuracy technology.
According to the company, this technology has been in development for nearly two decades and represents a major evolution in how CGM sensors operate.
Traditional CGM systems rely on fixed algorithms to interpret glucose data. The G8, however, is designed to adapt to individual physiology throughout the wear period, continuously adjusting to provide more consistent and reliable readings.
Dexcom says this approach may help reduce variability between users and improve overall sensor performance from day one through day fifteen.
The goal is simple: deliver glucose readings that are more accurate, more reliable, and more consistent throughout the entire life of the sensor.
Perhaps the most interesting part of Dexcom's announcement had little to do with glucose itself.
During the presentation, Dexcom revealed it is actively developing multi-analyte monitoring technology capable of monitor more than glucose, including ketones and potassium.
Why Potassium Monitoring Matters
Potassium plays a vital role in heart and muscle function.
When potassium levels become too high, a condition known as hyperkalemia can develop. This can occur in people with kidney disease and may lead to serious complications if left untreated.
Today, potassium levels are typically measured through laboratory blood tests.
A wearable sensor capable of continuously monitoring potassium could potentially provide earlier warning signs and support more proactive healthcare management. Although this technology still remains under development.
and ketones?
Dexcom also confirmed plans to incorporate ketone monitoring into the G8 platform in the future.
For people managing type 1 diabetes, ketone monitoring can be a major advance for diabetes safety
Ketones are produced when the body begins breaking down fat for energy and can increase rapidly during insulin shortages, illness, or episodes of diabetic ketoacidosis (DKA).
Currently, ketone testing requires blood or urine samples. A wearable sensor capable of continuously tracking ketones could provide earlier warnings and help users take action before a serious emergency develops.
While ketone monitoring will not be available at the initial launch of the G8, it remains one of the most exciting long-term developments discussed by the company.
While excitement around the G8 is growing, many questions remain unanswered.
Dexcom has not yet released details regarding:
While many questions remain, the announcement is expected to attract strong interest within the diabetes community, as it reflects a move toward more personalised and advanced diabetes technology.
The Dexcom G8 is still awaiting regulatory submission and is not expected to reach the market for several years,
Dexcom has indicated it expects to seek FDA clearance in 2027, with commercial availability potentially following regulatory review.
The Dexcom G8 appears to represent more than a routine product update.
By combining a smaller sensor, longer wear time, adaptive accuracy technology, and future multi-analyte monitoring, Dexcom is signalling a shift toward more intelligent and personalised biosensors.
While regulatory approval and real-world testing are still ahead, the G8 provides an early look at where diabetes technology may be heading over the next decade.
1. Is the Dexcom G8 available now?
No. Dexcom has announced the technology but has not yet submitted it for regulatory approval.
2. How long will the Dexcom G8 last?
Dexcom has indicated the G8 will provide up to 15 days of wear.
3. Will the G8 be smaller than the G7?
Yes. Dexcom says the G8 will be approximately 50% smaller than the current G7 sensor.
4. What is adaptive accuracy technology?
It is a new system designed to continuously adapt to individual physiology during wear to improve sensor consistency and accuracy.
5. Will the G8 monitor ketones?
Not at launch. Dexcom has confirmed ketone monitoring is planned for future versions of the platform.
6. Will the G8 monitor potassium?
Dexcom is actively developing potassium monitoring technology, although it is not expected to be available when the G8 first launches.
Explore our blog for more tips and resources on diabetes management.
Disclaimer: This blog is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your doctor or a qualified health provider with any questions about your condition. If you have a medical emergency, call 911 (US) or 000 (Australia) immediately, or visit your nearest emergency care center.
Discover more about our products and solutions to enhance your diabetes management journey. Join our community and experience the difference with Glucology today!